LSE · GDR.L
Genedrive Plc
£0.01-£0.00 (-0.92%)
Genedrive Plc’s quoted price sits in the lower half of its reported 52-week range, 37.68% below the high.
Loading market information…
LSE · N4P.L · GBp
Stock price, dividends, earnings
Quote as of Mar 17, 2026, 04:21 PM UTC. Cached market data; not a live quote.
One-year closing-price history · GBp. Historical prices are not a forecast.
N4 Pharma Plc’s quoted price sits in the lower half of its reported 52-week range, 52.5% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
N4 Pharma Plc’s forward annual dividend is £0.36 per share, paid semi-annual. The forward yield is 7,578.95% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow N4 Pharma Plc’s reporting calendar.
THE COMPANY BEHIND THE TICKER
N4 Pharma Plc is a specialized pharmaceutical company dedicated to creating advanced silica nanoparticle delivery platforms for pharmaceutical and biotechnology organizations throughout the United Kingdom. A core product is Nuvec, a non-viral adjuvant delivery system specifically designed for use in vaccine development and cancer therapies. Founded in 1979, the company is headquartered in London, UK.
Latest available per-share figures in GBP. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 08:27 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
£0.01-£0.00 (-0.92%)
Genedrive Plc’s quoted price sits in the lower half of its reported 52-week range, 37.68% below the high.
£0.07£0.00 (0.0%)
Tissue Regenix Group plc’s quoted price sits in the lower half of its reported 52-week range, 89.02% below the high.
£0.01+£0.00 (+4.29%)
Proteome Sciences plc’s quoted price sits in the lower half of its reported 52-week range, 66.82% below the high.
£0.09-£0.00 (-2.78%)
MyHealthChecked PLC’s quoted price sits in the lower half of its reported 52-week range, 58.33% below the high.
£0.00-£0.00 (-2.86%)
Theracryf Plc’s quoted price sits in the lower half of its reported 52-week range, 36.57% below the high.
£0.09£0.00 (0.0%)
CRISM Therapeutics Corporation’s quoted price sits in the lower half of its reported 52-week range, 52.7% below the high.
£0.00-£0.00 (-12.5%)
Surgical Innovations Group plc’s quoted price sits in the lower half of its reported 52-week range, 41.67% below the high.
£0.06-£0.00 (-1.79%)
Feedback plc’s quoted price sits in the lower half of its reported 52-week range, 63.33% below the high.
